In case you missed it, preclinical data published last week in Vaccines MDPI demonstrated the therapeutic potential of Vaxart’s mucosal vaccine technology platform. These data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of HPV-related tumorigenesis. Results also suggest that Vaxart’s mucosal vaccine platform holds promise in enabling a novel, non-invasive treatment for HPV-related cervical dysplasia. Read more in our press release here: https://t.co/Zb61JqnVqD
Vaxart, Inc.
Biotechnology Research
South San Francisco, California 8,409 followers
The pill that moves the needle.
About us
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.
- Website
-
https://vaxart.com
External link for Vaxart, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2004
- Specialties
- Biotechnology and Vaccines
Locations
-
Primary
290 Utah Ave
South San Francisco, California 94080, US
-
395 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Vaxart, Inc.
Updates
-
Happy Labor Day! Vaxart celebrates the incredible contributions of workers across all industries. Their commitment and drive are the backbone of innovation and progress. Here’s to the value of teamwork, perseverance, and the pursuit of excellence — thank you for your dedication! #LaborDay #Freedom #Vaxart #PillThatMovesTheNeedle
-
-
We are excited to share published preclinical data demonstrating the potential of our mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical dysplasia in the current issue of Vaccines MDPI. “The preclinical data published in Vaccines demonstrate that our mucosal vaccines stimulate T cells to destroy HPV-expressing cells, reducing the size of HPV-derived tumors and increasing the survival of mice bearing these tumors,” said Sean Tucker, Vaxart’s Founder and Chief Scientific Officer. Read more in today’s press release: https://bit.ly/476Tw9y
Vaxart, Inc. –Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
investors.vaxart.com
-
Vaxart CEO, Steven Lo, discusses the company’s progress achieved in its norovirus program, including positive top line results for our Phase 1 clinical trial, focused on lactating mothers. https://lnkd.in/d5UjWrSM #PillThatMovesTheNeedle #norovirus
Vaxart CEO Provides Q2 2024 Business Update - Part 3
https://www.youtube.com/
-
On the BARDA award, Vaxart CEO Steven Lo says it “underscores the opportunity we have to reimagine how vaccines are manufactured and distributed globally, and the urgency of our mission.” https://lnkd.in/dsVjRXmz #PillThatMovesTheNeedle #COVID19
Vaxart CEO Provides Q2 2024 Business Update - Part 2
https://www.youtube.com/
-
Vaxart CEO, Steven Lo, highlights the company’s key milestone in the first half of 2024, receiving one of the largest BARDA contracts to-date under Project NextGen, an award valued at up to $453 million. https://lnkd.in/dwfd_Pji #PillThatMovesTheNeedle #COVID19
Vaxart CEO Provides Q2 2024 Business Update - Part 1
https://www.youtube.com/
-
Data from the Centers for Disease Control and Prevention, reported in Newsweek, that for the first time a majority of states have “very high” levels of COVID-19 in their wastewater. Vaxart plans to initiate enrollment in a Phase 2b trial as early as the second half of 2024, pending alignment with FDA. bit.ly/3WZQyjV
-
Vaxart, Inc.'s Q2 2024 business update conference call begins at 4:30 p.m. ET today. Listen here: https://bit.ly/4dlf3gO #PillThatMovesTheNeedle #vaccines #GlobalHealth
-
Vaxart, Inc. today announced its Q2 2024 business update. The Company achieved meaningful progress on its goals during the first half of 2024, most significantly with its BARDA contract for its COVID-19 program under Project NextGen. https://bit.ly/4dilams #PillThatMovesTheNeedle #Vaxart #COVID19
Vaxart, Inc. –Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
investors.vaxart.com
-
From Endpoints: The U.S. Treasury has committed $667 million for a global Pandemic Fund, but Congress still must sign off. https://bit.ly/46tz5DN Vaxart is working to bring a potentially transformational approach to confronting future pandemics. #PillThatMovesTheNeedle #Vaxart #pandemicpreparedness
US bankrolls a third of global Pandemic Fund. Can it get congressional support?
endpts.com